SML0207
SB 328437
≥98% (HPLC)
别名:
L-Phenylalanine, N-(1-naphthalenylcarbonyl)-4-nitro-, methyl ester
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H18N2O5
化学文摘社编号:
分子量:
378.38
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
产品名称
SB 328437, ≥98% (HPLC)
InChI
1S/C21H18N2O5/c1-28-21(25)19(13-14-9-11-16(12-10-14)23(26)27)22-20(24)18-8-4-6-15-5-2-3-7-17(15)18/h2-12,19H,13H2,1H3,(H,22,24)/t19-/m0/s1
SMILES string
COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c2cccc3ccccc23
InChI key
VMFGCGRAIBLAFY-IBGZPJMESA-N
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: ≥10 mg/mL
originator
GlaxoSmithKline
storage temp.
2-8°C
Quality Level
Application
SB 328437 may be used to study CCR3-mediated cell signaling in asthma models.
Biochem/physiol Actions
SB 328437 inhibits the recruitment and migration of eosinophils in allergen models of models. It suppresses the Th2-mediated eosinophil infiltration in the airways.
SB-328437 is a CCR3 Antagonist.
SB-328437 is a potent, selective CCR-3 antagonist (IC50 = 1.6 nM). The compound blockes CCR3 agonist-induced calcium mobilization in CCR3 expressing cells with the following IC50 values: eotaxin, 38 nM; eotaxin-2, 35 nM and MCP4, 20 nM.
Features and Benefits
This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Akio Mori et al.
International immunology, 19(8), 913-921 (2007-09-07)
The effects of selective CC chemokine receptor (CCR)-3 antagonists on antigen-induced leukocyte accumulation in the lungs of mice adoptively transferred with in vitro-differentiated T(h)1 and T(h)2 were investigated. Inhalation of antigen by mice injected with T(h)1 and T(h)2 initiated the
Leyi Gong et al.
Expert opinion on therapeutic patents, 19(8), 1109-1132 (2009-07-30)
Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease. A patent literature review is presented of small molecule CCR3 antagonists comprising the
Yiwen Li et al.
PloS one, 6(2), e17106-e17106 (2011-03-02)
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical
商品
We offer many products related to chemokine receptors for your research needs.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持